PHS Technology Transfer Policy Board

 

Purpose: The purpose of the PHS Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board to the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), in establishing PHS technology transfer policies and modifying existing policies, as applicable.

 

Function: The function of the TTPB is:
  • to serve as an internal advisory board to the NIH, CDC, and FDA on all matters related to the Federal Technology Transfer Act (FTTA) and the PHS technology transfer program;
  • to recommend to the Director, NIH, PHS policies and agency procedures concerning the establishment, review, administration, and monitoring of Cooperative Research and Development Agreements (CRADAs) by PHS agencies, via the CRADA Review Subcommittee;
  • the CRADA Review Subcommittee reviews agreements and submits them to the Technology Transfer Policy Board for final approval recommendation. Generally, all CRADAs containing exclusive licensing-related clauses must be reviewed by the agency's CRADA Review Subcommittee;
  • to recommend to the Director, NIH, PHS policies and agency procedures concerning all aspects of patenting PHS inventions and discoveries;
  • to recommend to the Director, NIH, PHS policies and agency procedures concerning all aspects of licensing of intellectual property held by the PHS including the management and use of royalty fees received;
  • to provide, in conjunction with the NIH Office of Technology Transfer, on-going training and education of scientific and management staff of the NIH, CDC, and FDA on the laws, regulations, policies, and agency procedures as they relate to the FTTA and PHS technology transfer program.


    Structure: The TTPB shall consist of 13 full-time Federal employees, including the Chair. The members shall be:
  • Deputy Director for Intramural Research (Chair)
    Director, Office of Technology Transfer, NIH (Vice-Chair)
    One representative from the Office of Extramural Research, NIH
    The NIH Legal Advisor, nonvoting ex officio
    Two representatives from the Centers for Disease Control and Prevention (CDC)
    One representative from the Food and Drug Administration (FDA)
    Chair, Technology Development Coordinators (TDCs) Group
    Five representatives from the NIH Institutes and Centers (ICs), including
    • Three intramural scientists familiar with technology transfer issues
      Two administrative/management staff familiar with technology transfer issues